Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer

Akira Miyajima, Eiji Kikuchi, Takeo Kosaka, Mototsugu Oya

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalReviews on Recent Clinical Trials
Volume4
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Urogenital Neoplasms
Angiotensin II Type 1 Receptor Blockers
Angiogenesis Inhibitors
Neoplasms
Angiotensin Receptors
Renal Cell Carcinoma
Angiotensin II
Angiotensin Type 1 Receptor
Skin Neoplasms
Vasoconstrictor Agents
Growth
Angiotensin-Converting Enzyme Inhibitors
Carcinogenesis
Breast Neoplasms

Keywords

  • Angiogenesis
  • Angiotensin
  • Bladder
  • Kidney
  • Prostate
  • Receptor

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer. / Miyajima, Akira; Kikuchi, Eiji; Kosaka, Takeo; Oya, Mototsugu.

In: Reviews on Recent Clinical Trials, Vol. 4, No. 2, 2009, p. 75-78.

Research output: Contribution to journalArticle

@article{74bd3822e618418aac5fda0d863b1530,
title = "Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer",
abstract = "The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.",
keywords = "Angiogenesis, Angiotensin, Bladder, Kidney, Prostate, Receptor",
author = "Akira Miyajima and Eiji Kikuchi and Takeo Kosaka and Mototsugu Oya",
year = "2009",
doi = "10.2174/157488709788185996",
language = "English",
volume = "4",
pages = "75--78",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer

AU - Miyajima, Akira

AU - Kikuchi, Eiji

AU - Kosaka, Takeo

AU - Oya, Mototsugu

PY - 2009

Y1 - 2009

N2 - The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.

AB - The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.

KW - Angiogenesis

KW - Angiotensin

KW - Bladder

KW - Kidney

KW - Prostate

KW - Receptor

UR - http://www.scopus.com/inward/record.url?scp=67651166929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651166929&partnerID=8YFLogxK

U2 - 10.2174/157488709788185996

DO - 10.2174/157488709788185996

M3 - Article

C2 - 19463103

AN - SCOPUS:67651166929

VL - 4

SP - 75

EP - 78

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 2

ER -